Streetbeat News

Stock Prices

JACK

Jack in the Box has updated its fiscal year 2024 guidance, projecting EPS between $6.10 and $6.25, below the $6.30 estimate. Same-store sales are expected to decline by 1.0% for Jack in the Box and 1.5% for Del Taco. Adjusted EBITDA is forecasted to be between $320-$325 million.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 8:04 pm

AXON

Axon has raised its FY24 revenue outlook to a range of $2 billion to $2.05 billion, surpassing the previous estimate of $1.98 billion.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 8:04 pm

AXON

Axon Enterprise (NASDAQ:AXON) reported Q2 2024 adjusted EPS of $1.20, beating the estimate of $1.02. Sales were $589.129 million, surpassing the $477.957 million estimate and marking a 57.27% increase from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 8:03 pm

WYNN

Wynn Resorts (NASDAQ:WYNN) reported Q2 2024 earnings per share of $1.12, missing the analyst consensus estimate of $1.14 by 1.75%. The company also reported quarterly sales of $1.733 billion, missing the estimate of $1.752 billion by 1.11%. Despite the misses, sales increased by 8.58% compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 8:03 pm

TEM

Tempus AI (NASDAQ:TEM) reported Q2 sales of $165.969 million, surpassing the analyst consensus estimate of $145.807 million by 13.83%.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 8:03 pm

LUMN

Lumen Technologies (NYSE:LUMN) reported Q2 2024 adjusted EPS of $(0.13), missing the $(0.06) estimate by 116.67%. Sales were $3.268 billion, beating the $3.246 billion estimate by 0.69%. Compared to the same period last year, EPS decreased by 230% and sales decreased by 10.73%.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 8:02 pm

CRVS

Corvus Pharma (NASDAQ:CRVS) reported a Q2 EPS loss of $(0.07), beating the analyst estimate of $(0.12) by 41.67%. This represents a 50% improvement over the $(0.14) loss per share from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 8:02 pm

HALO

Halozyme Therapeutics (NASDAQ:HALO) reported Q2 earnings of $0.91 per share, beating the analyst estimate of $0.78 by 16.67%. Sales were $231.35M, surpassing the $208.90M estimate by 10.75%. Both earnings and sales showed year-over-year growth.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 8:02 pm

GO

Grocery Outlet Holding (NASDAQ:GO) reported Q2 2024 adjusted EPS of $0.25, beating the $0.20 estimate. Sales were $1.13 billion, surpassing the $1.10 billion estimate and marking an 11.88% increase from the previous year.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 8:01 pm

HIMS

Analysts have provided mixed ratings for Hims & Hers Health (NYSE:HIMS) over the past three months, with a notable increase in the average 12-month price target from $16.81 to $22.11. The company has shown strong financial performance, including a 45.81% revenue growth rate and a net margin of 4.0%.

Portfolio Pulse from Benzinga Insights

August 06, 2024 | 8:01 pm